INTRODUCTION: Although most previous cognitive studies of β-amyloidopathy in PD focused on cortical plaque deposition, recent postmortem studies point to an important role of striatal β-amyloid plaque deposition. The aim of this study was to investigate the relative contributions of striatal and cortical β-amyloidopathy to cognitive impairment in PD. METHODS: Patients with PD (n = 62; age, 68.9 ± 6.4 years; H & Y stage: 2.7 ± 0.5; MoCA score: 25.2 ± 3.0) underwent [(11) C]Pittsburgh compound B β-amyloid, [(11) C]dihydrotetrabenazine monoaminergic, and [(11) C]methyl-4-piperidinyl propionate acetylcholinesterase brain PET imaging and neuropsychological assessment. [(11) C]Pittsburgh compound B β-amyloid data from young to middle-aged healthy subjects were used to define elevated [(11) C]Pittsburgh compound B binding in patients. RESULTS: Elevated cortical and striatal β-amyloid deposition were present in 37% and 16%, respectively, of this predominantly nondemented cohort of patients with PD. Increased striatal β-amyloid deposition occurred in half of all subjects with increased cortical β-amyloid deposition. In contrast, increased striatal β-amyloid deposition did not occur in the absence of increased cortical β-amyloid deposition. Analysis of covariance using global composite cognitive z scores as the outcome parameter showed significant regressor effects for combined striatal and cortical β-amyloidopathy (F = 4.18; P = 0.02) after adjusting for covariate effects of cortical cholinergic activity (F = 5.67; P = 0.02), caudate nucleus monoaminergic binding, duration of disease, and age (total model: F = 3.55; P = 0.0048). Post-hoc analysis showed significantly lower cognitive z score for combined striatal and cortical β-amyloidopathy, compared to cortical-only β-amyloidopathy and non-β-amyloidopathy subgroups. CONCLUSIONS: The combined presence of striatal and cortical β-amyloidopathy is associated with greater cognitive impairment than cortical β-amyloidopathy alone in PD.
INTRODUCTION: Although most previous cognitive studies of β-amyloidopathy in PD focused on cortical plaque deposition, recent postmortem studies point to an important role of striatal β-amyloid plaque deposition. The aim of this study was to investigate the relative contributions of striatal and cortical β-amyloidopathy to cognitive impairment in PD. METHODS:Patients with PD (n = 62; age, 68.9 ± 6.4 years; H & Y stage: 2.7 ± 0.5; MoCA score: 25.2 ± 3.0) underwent [(11) C]Pittsburgh compound B β-amyloid, [(11) C]dihydrotetrabenazine monoaminergic, and [(11) C]methyl-4-piperidinyl propionateacetylcholinesterase brain PET imaging and neuropsychological assessment. [(11) C]Pittsburgh compound B β-amyloid data from young to middle-aged healthy subjects were used to define elevated [(11) C]Pittsburgh compound B binding in patients. RESULTS: Elevated cortical and striatal β-amyloid deposition were present in 37% and 16%, respectively, of this predominantly nondemented cohort of patients with PD. Increased striatal β-amyloid deposition occurred in half of all subjects with increased cortical β-amyloid deposition. In contrast, increased striatal β-amyloid deposition did not occur in the absence of increased cortical β-amyloid deposition. Analysis of covariance using global composite cognitive z scores as the outcome parameter showed significant regressor effects for combined striatal and cortical β-amyloidopathy (F = 4.18; P = 0.02) after adjusting for covariate effects of cortical cholinergic activity (F = 5.67; P = 0.02), caudate nucleus monoaminergic binding, duration of disease, and age (total model: F = 3.55; P = 0.0048). Post-hoc analysis showed significantly lower cognitive z score for combined striatal and cortical β-amyloidopathy, compared to cortical-only β-amyloidopathy and non-β-amyloidopathy subgroups. CONCLUSIONS: The combined presence of striatal and cortical β-amyloidopathy is associated with greater cognitive impairment than cortical β-amyloidopathy alone in PD.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: Nicolaas I Bohnen; Kirk A Frey; Stephanie Studenski; Vikas Kotagal; Robert A Koeppe; Gregory M Constantine; Peter J H Scott; Roger L Albin; Martijn L T M Müller Journal: Mov Disord Date: 2014-06-07 Impact factor: 10.338
Authors: Myria Petrou; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Roger L Albin; Kirk A Frey Journal: Neurology Date: 2012-08-29 Impact factor: 9.910
Authors: S Nagatsuka Si; K Fukushi; H Shinotoh; H Namba; M Iyo; N Tanaka; A Aotsuka; T Ota; S Tanada; T Irie Journal: J Cereb Blood Flow Metab Date: 2001-11 Impact factor: 6.200
Authors: Brittany N Dugger; Geidy E Serrano; Lucia I Sue; Douglas G Walker; Charles H Adler; Holly A Shill; Marwan N Sabbagh; John N Caviness; Jose Hidalgo; Megan Saxon-Labelle; Glenn Chiarolanza; Monica Mariner; Jonette Henry-Watson; Thomas G Beach Journal: J Parkinsons Dis Date: 2012-01-01 Impact factor: 5.568
Authors: Nicolaas I Bohnen; Martijn L T M Müller; Vikas Kotagal; Robert A Koeppe; Michael R Kilbourn; Sid Gilman; Roger L Albin; Kirk A Frey Journal: J Cereb Blood Flow Metab Date: 2012-05-09 Impact factor: 6.200
Authors: Yaroslau Compta; Laura Parkkinen; Sean S O'Sullivan; Jana Vandrovcova; Janice L Holton; Catherine Collins; Tammaryn Lashley; Constantinos Kallis; David R Williams; Rohan de Silva; Andrew J Lees; Tamas Revesz Journal: Brain Date: 2011-05 Impact factor: 13.501
Authors: Gaël Chételat; Renaud La Joie; Nicolas Villain; Audrey Perrotin; Vincent de La Sayette; Francis Eustache; Rik Vandenberghe Journal: Neuroimage Clin Date: 2013-03-05 Impact factor: 4.881
Authors: Jacob Haugen; Martijn L T M Müller; Vikas Kotagal; Roger L Albin; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen Journal: J Neural Transm (Vienna) Date: 2016-02-24 Impact factor: 3.575
Authors: Soo Hyun Cho; Jeong-Hyeon Shin; Hyemin Jang; Seongbeom Park; Hee Jin Kim; Si Eun Kim; Seung Joo Kim; Yeshin Kim; Jin San Lee; Duk L Na; Samuel N Lockhart; Gil D Rabinovici; Joon-Kyung Seong; Sang Won Seo Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-06 Impact factor: 9.236
Authors: Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri Journal: J Neurol Date: 2018-10-30 Impact factor: 4.849